The new office is located within Dubai Science Park
BeiGene, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, recently announced the first step in the company’s expansion in the Middle East and North Africa (MENA) region with the formal opening of its office in Dubai, United Arab Emirates.
Founded in 2010, BeiGene has built one of the largest and most efficient oncology research teams in the world, with a portfolio of 17 approved assets (3 internally developed) and a broad and deep pipeline focused on haematology and solid tumours with the potential to address 80 per cent of the world’s cancers by incidence.
The new office is located within Dubai Science Park, the region’s leading science-focused business community that is home to more than 450 customers and 5,500 professionals, and will house BeiGene’s administrative, commercial, and medical colleagues.
Significant step
“Our expansion into the Middle East and North Africa region is a significant step in our company’s ongoing global expansion and an opportunity to reinforce BeiGene’s commitment to deliver innovative, affordable and accessible medicines to more patients around the world,” commented Jurij Petrin, Head of New Market Development at BeiGene.
“Our presence at Dubai Science Park, with its state-of-the-art facilities, will best support our team and collaborations within the dynamic regional landscape to ensure patients across the region are able to equally access our innovative therapies,” remarked Mohammed Al-Kapany, General Manager, MENA.
“Greater collaboration in the healthcare and biotechnology sector is essential to deliver breakthrough innovations that can improve survival rates and long-term outcomes for patients,” noted Marwan Abdulaziz Janahi, Senior Vice President, Dubai Science Park, part of TECOM Group.
